



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

Tidutamab

Cat. No.:	HY-P99562
CAS No.:	2148354-90-7
Target:	CD3
Pathway:	Immunology/Inflammation
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

BIOLOGICAL ACTIVITY

Description	Tidutamab (XmAb-18087) is a humanized and affinity-optimized bispecific antibody (bsAb) targeting SSTR2 binding domain and T-cell binding domain (CD3). Tidutamab possesses a full Fc domain to maintain long serum half-life. Tidutamab eliminates SSTR+ tumor cells by stimulating redirected T cell mediated cytotoxicity (RTcC) ^[1] .	
In Vitro	Tidutamab (XmAb-18087; 0-100.000 ng/mL) binds to human SSTR2+ CHO cells with an ED ₅₀ value of 2.2 µg/mL and mediates T cell killing of SSTR2+ target cells ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.	
In Vivo	Tidutamab (XmAb-18087; 3 mg/kg; i.p.; single dose) stimulates human T cell killing of SSTR2+ A549 lung carcinoma tumors in NSG mice ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.	
	Animal Model:	NSG mice ^[1]
	Dosage:	3 mg/kg
	Administration:	Intraperitoneal injection; single dose
	Result:	Induced anti-tumor activity in human PBMC-engrafted NSG mice.

REFERENCES

[1]. Hyung LS, et, al. Anti-SSTR2 × anti-CD3 bispecific antibody induces potent killing of human tumor cells in vitro and in mice, and stimulates target-dependent T cell activation in monkeys: A potential immunotherapy for neuroendocrine tumors. *Cancer Res* (2017) 77 (13_Supplement): 3633.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA